AN2 Therapeutics, Inc.
ANTX
$1.15
$0.043.60%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | 55.23% | 35.92% | 55.49% | 23.70% | 8.66% |
Total Depreciation and Amortization | -- | -- | -- | -- | -- |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 23.03% | 23.96% | 30.99% | -23.41% | -8.12% |
Change in Net Operating Assets | -113.23% | 30.44% | 194.53% | -112.76% | -190.05% |
Cash from Operations | 47.17% | 39.61% | 69.11% | -1.75% | -12.16% |
Capital Expenditure | -- | -- | -- | -- | -- |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -64.56% | -65.03% | -1,738.10% | 129.97% | 108.96% |
Cash from Investing | -64.56% | -65.03% | -1,738.10% | 129.97% | 108.96% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -- | -81.38% | -- | -99.97% | -100.00% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -- | -81.38% | 100.00% | -99.97% | -100.00% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -185.02% | -115.10% | 28.38% | 182.17% | -85.28% |